Claims for Patent: 9,995,746

Summary for Patent: 9,995,746

Title:	Rapid dual direct fluorescent antibody assay for the identification of Bacillus antrhacis
Abstract:	In this application is described a method for rapidly and accurately identifying B. anthracis in a sample by simultaneously detecting the presence of cell wall antigen and capsule antigen in the same sample culture grown under capsule inducing conditions. Other uses and advantages of the method of the invention are described herein.
Inventor(s):	Abshire; Teresa (Frederick, MD), Ribot; Wilson J (Hanover, PA)
Assignee:	The United States of America, as represented by the Secretary of the Army (Washington, DC)
Application Number:	15/125,910
Patent Claims:	1. A method for detecting the presence of Bacillus anthracis in a sample, said method comprising (i) culturing for 2-3 hours a single sample under conditions suitable to induce formation of Bacillus anthracis capsule, and thereby producing a single cultured sample; (ii) directly following step (i), contacting said single cultured sample in a single container means with two antibodies in tandem, antibodies one and Fab antibody two, each detectably labeled with a different identifiable signal moiety, such that said two antibodies are present in the same culture sample together in said single container means, wherein antibody one specifically binds to a capsule antigen, and Fab antibody two has a radius sufficiently small so as to permeate the Bacillus anthracis capsule, and Fab antibody two specifically binds to a cell wall antigen, and binds to the cell wall antigen even in the presence of capsule-inducing conditions; and (iii) detecting the presence of the detectable signal from antibody one and Fab antibody two wherein the presence of detectable signal from both antibodies indicates presence of Bacillus anthracis in said single cultured sample. 2. The method of claim 1, wherein antibody one specifically binds to Bacillus anthracis capsule poly-D-glutamic acid. 3. The method of claim 2, wherein antibody one is mAb FDF-1B9. 4. The method of claim 1 wherein Fab antibody two specifically binds to Bacillus anthracis cell wall galactose-N-acetyl-glucosamine. 5. The method of claim 4 wherein said Fab antibody two is mAb EAII-6G6 Fab. 6. The method of claim 3 wherein said Fab antibody two is mAb EAII-6G6 Fab. 7. The method of claim 1 wherein antibody one and Fab antibody two are labeled with a contrasting fluorophore. 8. The method of claim 7 wherein the fluorophore is fluorescein isothiocyanate, rhodamine, luciferin, auramine, sulforhodamine 101 acid chloride, carboxamido-(6-azidohexanyl), triethyammonium salt, or AMCA blue. 9. The method of claim 1, wherein the sample is a forensic sample. 10. The method of claim 1 wherein said sample is a biological sample obtained from a subject, which biological sample includes one or more of cells, blood, tissues, or biological fluid. 11. The method of claim 1, wherein the sample is selected from the group consisting of soil, water, or food product. 12. The method of claim 1, wherein the Fab antibody two has a Stokes radius 4.6 nm or less. 13. The method of claim 1, wherein the Fab antibody two has a Stokes radius 3.2 nm or less. 14. A method for detecting the presence of Bacillus anthracis in a single sample, without first culturing the sample, said method comprising (i) contacting a single sample with two antibodies in tandem in a single container means, antibodies one and Fab antibody two, each detectably labeled with a different identifiable signal moiety wherein cells in the sample are intact and in vegetative form, uncultured, and less than 24 hours old, antibody one specifically binds to a capsule antigen, and Fab antibody two has a radius sufficiently small so as to permeate the Bacillus anthracis capsule, and Fab antibody two specifically binds to a cell wall antigen, and binds to the cell wall antigen even in the presence of capsule-inducing conditions; and (ii) detecting the presence of the detectable signal from antibody one and Fab antibody two wherein the presence of detectable signal from both antibodies indicates presence of Bacillus anthracis in said single sample. 15. The method of claim 14, which comprises the further steps for confirming the results of step (ii) by (iii) incubating the sample for 2-3 hours, under conditions suitable to induce formation of Bacillus anthracis capsule, thereby producing a single cultured sample, (iv) directly following step (iii), contacting said single cultured sample in said single container means with two antibodies in tandem, antibodies one and Fab antibody two, each detectably labeled with a different identifiable signal moiety wherein antibody one specifically binds to a capsule antigen, and Fab antibody two has a radius sufficiently small so as to permeate the Bacillus anthracis capsule, and Fab antibody two specifically binds to a cell wall antigen, and binds to the cell wall antigen even in the presence of capsule-inducing conditions; and (v) detecting the presence of the detectable signal from antibody one and Fab antibody two wherein the presence of detectable signal from both antibodies indicates presence of Bacillus anthracis in said single cultured sample. 16. The method of claim 14, wherein antibody one specifically binds to Bacillus anthracis capsule poly-D-glutamic acid, and wherein Fab antibody two specifically binds to Bacillus anthracis cell wall galactose-N-acetyl-glucosamine.

Details for Patent 9,995,746

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2040-01-28